Excellent PFS and OS of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib, Bendamustine, and Dexamethasone (KBD): A 6.5 Year Follow-up

Hughes, M. S., Leng, S., Chakraborty, R., Bhutani, D., Mapara, M., Raza, S., & Lentzsch, S. (2023). Excellent PFS and OS of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib, Bendamustine, and Dexamethasone (KBD): A 6.5 Year Follow-up. Blood, 142(Supplement 1), 6576–6576. https://doi.org/10.1182/blood-2023-182842
Authors:
Michael Sang Hughes
Siyang Leng
Rajshekhar Chakraborty
Divaya Bhutani
Markus Y. Mapara
Shahzad Raza
Suzanne Lentzsch
Affiliated Authors:
Michael Sang Hughes
Rajshekhar Chakraborty
Divaya Bhutani
Markus Y. Mapara
Suzanne Lentzsch
Columbia Affiliation:
Subjects:
Diagnosis and Treatment of Multiple Myeloma (OpenAlex Topic)
Role of Pim Oncogenes in Tumorigenesis (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1182/blood-2023-182842
DOI:
10.1182/blood-2023-182842
Journal:
Blood
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: